NeutraKine® BMP-7 Monoclonal antibody
NeutraKine® BMP-7 Monoclonal Antibody for FC (Intra), Neutralization, ELISA
Host / Isotype
Mouse / IgG1
Reactivity
human, mouse
Applications
FC (Intra), Neutralization, ELISA
Conjugate
Unconjugated
CloneNo.
3E9G7
Cat no : 69011-1-Ig
Synonyms
Validation Data Gallery
| Neutralization |
Product Information
69011-1-Ig targets NeutraKine® BMP-7 in FC (Intra), Neutralization, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | human Humankine BMP-7 protein HZ-1229 相同性解析による交差性が予測される生物種 |
| Full Name | bone morphogenetic protein 7 |
| Gene symbol | BMP7 |
| Gene ID (NCBI) | 655 |
| RRID | AB_2882929 |
| Conjugate | Unconjugated |
| Form | Lyophilized Powder |
| Purification Method | Protein G purification |
| Storage Buffer | Sterile PBS. |
| Endotoxin | <0.1 EU/μg |
| Reconstitution | This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use. |
| Stability and Storage | Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products. |
Background Information
The bone morphogenetic proteins (BMPs) are a family of secreted signaling molecules that can induce ectopic bone growth. Many BMPs are part of the transforming growth factor-beta (TGFB) superfamily. BMPs were originally identified by an ability of demineralized bone extract to induce endochondral osteogenesis in vivo in an extraskeletal site.
BMP7, also known as osteogenic protein-1 or OP-1, plays a key role in the transformation of mesenchymal cells into bone and cartilage. BMP7 may be involved in bone homeostasis (PMID: 15621726). It is expressed in the brain, kidneys and bladder. BMP7 is also present in cancers, including breast, prostate, and colon cancers, in which it is implicated in regulating cancer cell proliferation (PMID: 16419056, PMID: 15531927). Overexpression of BMP7 mRNA in colorectal cancer patients was significantly associated with poor prognosis and low overall survival (PMID: 18259822). Recent studies suggest that high-expression level of BMP7 serves as a biomarker for poor prognosis for HCC (PMID: 23179403).
This antibody can be used to neutralize the bioactivity of BMP-7.
